caa a22 4500 445332239 CHVBK 20180317142741.0 cr unu---uuuuu 170323e20110601xx s 000 0 eng 10.1007/s10198-010-0224-8 doi (NATIONALLICENCE)springer-10.1007/s10198-010-0224-8 Utilities and disutilities for attributes of injectable treatments for type 2 diabetes [Elektronische Daten] [Kristina Boye, Louis Matza, Kimberly Walter, Kate Van Brunt, Andrew Palsgrove, Aodan Tynan] Introduction: Although cost-utility models are frequently used to estimate treatment outcomes for type 2 diabetes, utilities are not available for key attributes of injectable treatments. The purpose of this study was to identify the utility or disutility of three injection-related attributes (dose frequency, dose flexibility, injection site reaction) that may influence patient preference. Methods: Patients with type 2 diabetes in Scotland completed standard gamble (SG) interviews to assess the utility of hypothetical health states and their own current health state. The EQ-5D, PGWB, IWQOL-Lite, and QIDS were also administered. Construct validity and differences among health states were examined. Results: A total of 151 patients completed interviews. Of the three injection-related attributes, dose frequency was the only attribute with a statistically significant impact on utility (in a multiple regression model, p=0.01). Weekly injections were associated with an average added utility of 0.023 in comparison to everyday injections. Flexible dosing and injection site reactions resulted in somewhat smaller utility shifts that were in the expected directions (+0.006 and −0.011, respectively). SG utility of current health (mean=0.897) demonstrated construct validity through statistically significant correlations with patient-reported outcome measures. Discussion: The three injection attributes were associated with small utility shifts in the expected directions. Dose frequency appears to be the most important of the three attributes from the patients' perspective. The vignette-based SG approach was feasible and useful for assessing added utility or disutility of injection-related attributes associated with treatments for type 2 diabetes. Springer-Verlag, 2010 Utilities nationallicence Type 2 diabetes nationallicence Injection nationallicence Dose frequency nationallicence Patient preference nationallicence Standard gamble nationallicence Boye Kristina Eli Lilly and Company, Indianapolis, IN, USA aut Matza Louis Center for Health Outcomes Research, United BioSource Corporation, 7101 Wisconsin Avenue, Suite 600, 20814, Bethesda, MD, USA aut Walter Kimberly Center for Health Outcomes Research, United BioSource Corporation, 7101 Wisconsin Avenue, Suite 600, 20814, Bethesda, MD, USA aut Van Brunt Kate Center for Health Outcomes Research, United BioSource Corporation, 7101 Wisconsin Avenue, Suite 600, 20814, Bethesda, MD, USA aut Palsgrove Andrew Center for Health Outcomes Research, United BioSource Corporation, 7101 Wisconsin Avenue, Suite 600, 20814, Bethesda, MD, USA aut Tynan Aodan Eli Lilly and Company, Indianapolis, IN, USA aut The European Journal of Health Economics Springer-Verlag 12/3(2011-06-01), 219-230 1618-7598 12:3<219 2011 12 10198 https://doi.org/10.1007/s10198-010-0224-8 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10198-010-0224-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Boye Kristina Eli Lilly and Company, Indianapolis, IN, USA aut NATIONALLICENCE 700 1- Matza Louis Center for Health Outcomes Research, United BioSource Corporation, 7101 Wisconsin Avenue, Suite 600, 20814, Bethesda, MD, USA aut NATIONALLICENCE 700 1- Walter Kimberly Center for Health Outcomes Research, United BioSource Corporation, 7101 Wisconsin Avenue, Suite 600, 20814, Bethesda, MD, USA aut NATIONALLICENCE 700 1- Van Brunt Kate Center for Health Outcomes Research, United BioSource Corporation, 7101 Wisconsin Avenue, Suite 600, 20814, Bethesda, MD, USA aut NATIONALLICENCE 700 1- Palsgrove Andrew Center for Health Outcomes Research, United BioSource Corporation, 7101 Wisconsin Avenue, Suite 600, 20814, Bethesda, MD, USA aut NATIONALLICENCE 700 1- Tynan Aodan Eli Lilly and Company, Indianapolis, IN, USA aut NATIONALLICENCE 773 0- The European Journal of Health Economics Springer-Verlag 12/3(2011-06-01), 219-230 1618-7598 12:3<219 2011 12 10198 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer